Home » Newsletters » BioWorld Science

BioWorld Science

Feb. 12, 2010

View Archived Issues

Novel M. tuberculosis methionine aminopeptidase inhibitors identified

Variations in fentanyl sensitivity correlated with OPRM1 gene polymorphisms

Gene recurrence score may be useful for prognosis in node-positive breast cancer

Javelin reports phase III trial data for Ereska

Nymox provides update on pivotal phase III NX-1207 trials for BPH

Phase II study evaluates droxidopa in combination with carbidopa in adult ADHD

StemCells' HuCNS-SC human neural stem cells used in myelination disorder trial

FDA accepts Alexza's AZ-004 NDA for filing

Data Monitoring Committee recommends continuation of phase III StemEx trial

Correlation between higher blood lead levels and adverse mental health outcomes

Oral cladribine reduces rate of multiple sclerosis relapse in phase III trial

LEK Pharmaceuticals describes novel broad spectrum antibacterial agents

Amura Therapeutics discovers novel CAC1 cysteine protease inhibitors

Aegera presents novel IAP inhibitors

Otsuka Pharmaceutical describes novel monoamine reuptake inhibitors

Ligon Discovery and Lycera collaborate to develop drugs for immune disorders

Data Monitoring Committee recommends continuation of phase III ThermoDox trial

QRxPharma initiates second pivotal phase III MoxDuoIR dual-opioid trial

Antisense provides update on ATL-1101

Astellas reports third quarter 2009 results

Lundbeck claims the identification of novel PDE10 inhibitors

FDA grants approval to Daiichi's hypertension treatment Benicar in pediatric patients

Living Cell Technologies receives government grant for Diabecell

3SBio and Ascentage enter into strategic alliance for targeted cancer therapeutics

Shenogen and Chemizon sign agreement for ERalpha receptor modulators

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Aug. 3, 2026.
Tuojie Biotech (Shanghai) synthesizes new SARM1 inhibitors
BioWorld Science
Tuojie Biotech (Shanghai) Co. Ltd. has prepared and tested NAD(+) hydrolase SARM1 (SAMD2; MyD88-5) inhibitors found to be potentially useful for the treatment of...
Death in Chinese gene-editing trial exposes ethical fault lines
BioWorld
The death of a 6-year-old girl after receiving an experimental brain-directed gene-editing therapy at the Xinhua Hospital in Shanghai has reopened debate over how...
Seed funding at Adjuvia to treat mitochondrial dysfunction
BioWorld Science
Adjuvia Therapeutics Inc. has closed a $8 million series seed financing round to advance its work developing therapeutics to treat mitochondrial dysfunction and...
Replimune’s RP-1 for melanoma wins over FDA adcom
BioWorld
Following two complete response letters in the past year, Replimune Group Inc.’s RP-1 (suvolimogene oderparepvec) for unresectable metastatic cutaneous melanoma...